|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Cymabay Therapeutics, Inc. (CBAY) |
|
|
$32.48 0.00 (0.00%) as of 4:30 Thu 3/21
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
114,780,000 |
Market
Cap: |
3.73(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$7.47 - $32.48 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
51,301 |
Total Buy Value |
$0 |
$0 |
$0 |
$100,037 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
6,000 |
235,302 |
552,511 |
672,611 |
Total Sell Value |
$191,849 |
$4,692,766 |
$8,944,114 |
$10,085,429 |
Total People Sold |
1 |
5 |
6 |
7 |
Total Sell Transactions |
1 |
14 |
33 |
36 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mcwherter Charles |
President of R&D |
|
2023-12-18 |
4 |
OE |
$5.00 |
$56,660 |
D/D |
11,332 |
21,504 |
|
- |
|
Menold Daniel |
Vice President, Finance |
|
2023-12-15 |
4 |
AS |
$21.98 |
$472,646 |
D/D |
(21,497) |
0 |
|
47% |
|
Menold Daniel |
Vice President, Finance |
|
2023-12-15 |
4 |
OE |
$4.05 |
$137,420 |
D/D |
21,497 |
11,497 |
|
- |
|
Quinlan Paul T |
General Counsel |
|
2023-12-15 |
4 |
AS |
$21.98 |
$109,903 |
D/D |
(5,000) |
0 |
|
47% |
|
Quinlan Paul T |
General Counsel |
|
2023-12-15 |
4 |
OE |
$2.94 |
$14,700 |
D/D |
5,000 |
5,000 |
|
- |
|
Shah Sujal |
Chief Executive Officer |
|
2023-12-11 |
4 |
AS |
$19.99 |
$1,297,170 |
D/D |
(64,865) |
171,301 |
|
58% |
|
Shah Sujal |
Chief Executive Officer |
|
2023-12-11 |
4 |
OE |
$5.00 |
$324,325 |
D/D |
64,865 |
172,191 |
|
- |
|
Dorling Janet |
Director |
|
2023-12-11 |
4 |
AS |
$20.07 |
$120,422 |
D/D |
(6,000) |
0 |
|
58% |
|
Dorling Janet |
Director |
|
2023-12-11 |
4 |
OE |
$4.63 |
$27,780 |
D/D |
6,000 |
6,000 |
|
- |
|
Mcwherter Charles |
President of R&D |
|
2023-11-17 |
4 |
AS |
$18.28 |
$207,293 |
D/D |
(11,342) |
15,000 |
|
77% |
|
Mcwherter Charles |
President of R&D |
|
2023-11-17 |
4 |
OE |
$5.00 |
$56,710 |
D/D |
11,342 |
26,342 |
|
- |
|
Menold Daniel |
Vice President, Finance |
|
2023-11-15 |
4 |
AS |
$17.38 |
$0 |
D/D |
(0) |
0 |
|
80% |
|
Menold Daniel |
Vice President, Finance |
|
2023-11-15 |
4 |
OE |
$3.45 |
$60,375 |
D/D |
17,500 |
17,500 |
|
- |
|
Quinlan Paul T |
General Counsel |
|
2023-11-15 |
4 |
AS |
$17.38 |
$86,889 |
D/D |
(5,000) |
0 |
|
80% |
|
Quinlan Paul T |
General Counsel |
|
2023-11-15 |
4 |
OE |
$2.94 |
$14,700 |
D/D |
5,000 |
5,000 |
|
- |
|
Shah Sujal |
Chief Executive Officer |
|
2023-11-13 |
4 |
AS |
$15.89 |
$1,030,660 |
D/D |
(64,863) |
171,301 |
|
93% |
|
Shah Sujal |
Chief Executive Officer |
|
2023-11-13 |
4 |
OE |
$5.00 |
$324,315 |
D/D |
64,863 |
192,156 |
|
- |
|
Dorling Janet |
Director |
|
2023-11-10 |
4 |
AS |
$15.24 |
$106,700 |
D/D |
(7,000) |
0 |
|
99% |
|
Dorling Janet |
Director |
|
2023-11-10 |
4 |
OE |
$4.63 |
$32,410 |
D/D |
7,000 |
7,000 |
|
- |
|
Mcwherter Charles |
President of R&D |
|
2023-10-18 |
4 |
AS |
$14.07 |
$305,941 |
D/D |
(21,743) |
15,000 |
|
136% |
|
Mcwherter Charles |
President of R&D |
|
2023-10-18 |
4 |
OE |
$5.00 |
$108,715 |
D/D |
21,743 |
36,743 |
|
- |
|
Quinlan Paul T |
General Counsel |
|
2023-10-16 |
4 |
AS |
$13.76 |
$68,798 |
D/D |
(5,000) |
0 |
|
124% |
|
Quinlan Paul T |
General Counsel |
|
2023-10-16 |
4 |
OE |
$2.94 |
$14,700 |
D/D |
5,000 |
5,000 |
|
- |
|
Menold Daniel |
Vice President, Finance |
|
2023-10-16 |
4 |
AS |
$13.76 |
$0 |
D/D |
(0) |
0 |
|
124% |
|
Menold Daniel |
Vice President, Finance |
|
2023-10-16 |
4 |
OE |
$3.45 |
$60,375 |
D/D |
17,500 |
17,500 |
|
- |
|
156 Records found
|
|
Page 2 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|